Developmental Processes in Schizophrenic Disorders: Cognitive Remediation, Medication Adherence, and Work Outcome in Recent-Onset Schizophrenia.

Trial Profile

Developmental Processes in Schizophrenic Disorders: Cognitive Remediation, Medication Adherence, and Work Outcome in Recent-Onset Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2015

At a glance

  • Drugs Risperidone (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Oct 2011 Planned end date changed from 1 Mar 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Ortho-McNeil-Janssen Pharmaceuticals added as trial sponsor and lead trial center as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top